Sebia India Private Limited has been honoured as the Top Emerging MedTech Company at the prestigious BioSpectrum Excellence Awards 2025, a recognition that celebrates outstanding contributions and leadership in the Indian healthcare and diagnostics industry.
The BioSpectrum Excellence Awards—hosted by a leading global, insight-driven market research organisation—acknowledge companies that demonstrate innovation, impact, and growth. The award was presented by Dr Jitendra Singh, Minister of Science & Technology, Government of India, during a ceremony held at the India Habitat Centre, New Delhi.
A distinguished five-member jury panel comprising experts from academia, investment, consulting, public policy, and incubation evaluated and shortlisted Sebia India for this honour. Press releases regarding the ceremony and winners have been widely shared across major social networking platforms.
This milestone comes at a remarkable time, as Sebia India marks six remarkable years of operations in the country
“This is a great moment for us as we continue delivering innovative diagnostic solutions to leading laboratories and hospitals across India,” said Heejin Roh, Vice President – Commercial Operations, Asia-Pacific, Sebia, on receiving the award, expressing heartfelt gratitude to customers, partners, and patrons for their trust and unwavering support, and reaffirming that Sebia will continue strengthening its portfolio in India through scientific collaborations, new technology launches, and expanded clinical education initiatives.
As a global leader in speciality diagnostics, Sebia is widely recognised for its pioneering solutions in multiple myeloma screening and monitoring, hemoglobinopathies, HbA1c testing, newborn screening, and autoimmune diseases. The company’s advanced technologies—including capillary electrophoresis systems and the Alegria platform—have been instrumental in supporting accurate, reliable, and high-quality diagnostics across India’s leading hospital chains and laboratories.
